Cecile Chartier Email Address

Chief Scientific Officer

Iovance Biotherapeutics develops T-cell-based immunotherapy products for the treatment of cancer.

- Project Team Leader with extensive experience leading cross-functional teams focused on the development of novel therapeutics from pre-IND to Phase I. - Senior Director of Target Validation, providing direction and leadership to a Research Group dedicated to the identification and validation of new therapeutic targets for Immuno-Oncology. - Creative scientist with in-depth knowledge of Cancer, Immuno-Oncology, Stem Cell Biology, and Signaling Pathways. - Molecular Biologist familiar with most in vitro and in vivo study systems, including viral vectors, GEMMs, and PDX and syngeneic tumor mouse models. - Extensive industry experience in the Antibody Therapeutics and Gene & Cell Therapy fields. - Excellent communicator.